Table 3.
Summary of results from adjusted logistic regression analyses at weeks 4 and 48 and longitudinal analyses
| HIVI-SI bothersome symptom | Baseline | Week 4 | Week 48 | Longitudinal model | Description of longitudinal findings |
|---|---|---|---|---|---|
| Group 1: Bothersome symptoms with decreased prevalence at week 4 and maintained through week 48 | |||||
| Nightmare | † | ✓* | ✓ | ✓ | Decreased prevalence in both groups from week 4 to week 48, with lower prevalence in switch group |
| Vivid dreams | † | ✓* | ✓* | ✓ | Decreased prevalence in both groups from week 4 to week 48 with lower prevalence in switch group |
| Weird/intense dreams | † | ✓ | ✓ | ✓ | Switch group decreased prevalence maintained over study period without any changes in prevalence from week 4 to week 48 |
| Dizzy/lightheadedness | ✓* | ✓ | ✓ | Switch group decreased prevalence maintained over study period without any changes in prevalence from week 4 to week 48 | |
| Fatigue/loss of energy | ✓ | ✓ | Switch group decreased prevalence maintained over study period without any changes in prevalence from week 4 to week 48 | ||
| Pain/numbness/tinging in hands/feet | ✓ | ✓ | ✓ | Switch group decreased prevalence maintained over study period without any changes in prevalence from week 4 to week 48 | |
| Group 2: Bothersome symptoms with early decreases and longitudinal time by treatment interaction | |||||
| Nervous/anxious | ✓ | ✓‡ | Switch group with fluctuating prevalence (week 48 lower than baseline); no-switch group with decreased prevalence from week 4 to week 48 | ||
| Drowsy | ✓ | ✓‡ | Switch group with fluctuating prevalence (week 48 similar to baseline); no-switch group with decreased prevalence from week 4 to week 48 | ||
| Group 3: Bothersome symptoms with differences in prevalence longitudinally | |||||
| Difficulty Sleeping | ✓ | Switch group decreased prevalence maintained over study period without any changes in prevalence from week 4 to week 48 | |||
| Diarrhea/loose bowels | ✓ | Switch group decreased prevalence maintained over study period without any changes in prevalence from week 4 to week 48 | |||
| Bloating/pain/gas in stomach | × | No-switch group decreased prevalence maintained from week 4 to week 48 | |||
| Group 4: Bothersome symptoms with decreased prevalence only at week 4 | |||||
| Trouble remembering | ✓ | No differences in prevalence observed between the groups from week 4 to week 48 | |||
| Feeling off balance | ✓ | No differences in prevalence observed between groups from week 4 to week 48 | |||
| Changes in body composition | ✓ | ‡ | No differences in prevalence observed between groups from week 4 to week 48 | ||
* Also significant in unadjusted model
†Statistically significantly higher prevalence in the switch group
‡Statistically significant time-by-treatment interaction
✓ Statistically significant reduction for the switch group
× Statistically significant reduction for the no-switch group